Expanded Access to RXDX-105 for Cancers With RET Alterations

NO_LONGER_AVAILABLE

Conditions studied: Cancers With RET Alterations

In brief

Expanded access to RXDX-105 will be given to patients with cancers harboring RET alterations who have not received TKIs that target RET alterations, who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for RXDX-105.

Key facts

Study ID

NCT03052569

Run by

Hoffmann-La Roche

Last updated by the study team

2019-04-26

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of advanced cancer with RET alterations
• Unable to participate in an ongoing RXDX-105 clinical trial
• Willing and able to provide written, signed informed consent
• Medically suitable for treatment with RXDX-105

You may not qualify if…

• Prior treatment with a TKI that has activity against RET alterations
• Currently enrolled in an ongoing clinical study with any other investigational agent

Where it is running

• Www.Ignyta.Com — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.